Physician profile
Jared Jones
NPI 1700347986
$2,593.44
in general payments reported to CMS, 2019-2025
31 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $132 · 2023: $591 · 2024: $740 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.39 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.22 | 2023-2025 | |
| Novo Nordisk INC | $330.04 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $232.03 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.34 | 2025 | Caplyta |
| Amgen INC. | $163.56 | 2025 | Evenity, Repatha, Prolia |
| Radius Health, INC. | $133.26 | 2023-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.67 | 2022-2025 | Xifaxan |
| Pfizer INC. | $96.18 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $65.50 | 2024-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $56.53 | 2022-2023 | Verquvo, Belsomra, Steglujan |
| Sanofi-Aventis U.S. LLC | $56.51 | 2022-2023 | |
| Lilly USA, LLC | $55.40 | 2023-2025 | Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $54.27 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Corium, LLC | $51.65 | 2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $46.06 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $44.67 | 2022-2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $41.00 | 2023-2024 | Gvoke Hypopen |
| Tris Pharma INC | $34.80 | 2023-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $33.33 | 2023-2025 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $26.10 | 2024 | Austedo Xr |
| Abbott Laboratories | $23.80 | 2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $18.64 | 2022 | |
| Esperion Therapeutics, INC. | $18.49 | 2025 | Nexletol |
| Viatris Specialty LLC | $18.17 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $18.06 | 2024 | Gemtesa |
| Averitas Pharma INC. | $16.54 | 2023 | Qutenza |
| Exact Sciences Corporation | $14.69 | 2025 | The Cologuard Plus Collection Kit |
| Insulet Corporation | $14.54 | 2023 | Omnipod |
| Verity Pharmaceuticals INC. | $14.42 | 2025 | Tlando |
| Ucb, INC. | $13.73 | 2023 | |
| Mylan Specialty L.P. | $13.24 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.